Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil and Herceptin in Advanced Breast Cancer
NCT00006825Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jul 2000
- Primary completion
- Jul 2004
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and trastuzumab in breast cancer, sponsored by NYU Langone Health. Primary endpoints: Toxicity, including cardiac toxicity and Efficacy of the regimen. Started Jul 2000; status: completed.
02
Drugs
doxorubicintrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006825.